Revance Therapeutics is a biotechnology company focused on developing transformative neuromodulators to address a broad spectrum of aesthetic and therapeutic conditions. Revance’s lead product candidate, DaxibotulinumtoxinA for Injection (DAXI), utilizes a unique proprietary peptide excipient technology combined with highly purified botulinum toxin type A to produce a novel, longacting neuromodulator set to enter a $4.5 billion global market. In aesthetics, Revance successfully completed its Phase 3 program for DAXI in glabellar (frown) lines and is currently pursuing U.S. regulatory approval in 2020, while also running two separate Phase 2 studies in forehead lines and lateral canthal lines (crow’s feet). In therapeutics, DAXI is being studied in three indications, including a Phase 3 trial in cervical dystonia, a Phase 2 trial in adult upper limb spasticity, and a Phase 2 trial in plantar fasciitis, with plans to also study migraine. Beyond DAXI, Revance also has begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace.
“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc. BOTOX® is a registered trademark of Allergan, Inc.
Copyright West LLC. Minimum 15 minutes delayed.
INVESTOR RELATIONS CONTACTS
Jeanie D. Herbert
Sr. Director, Investor Relations
Revance Therapeutics, Inc.
P.O. Box 303
Newark, California 94560-0303
Phone: (510) 742-3400
Fax: (510) 742-3401
+1 (877) 373 6374
(US, Canada, Puerto Rico)
+1 (781) 575 3120 (non-US)
Shareholder Correspondence should
be mailed to:
P.O. Box 505000
Louisville, KY 40233
correspondence should be sent to:
462 South 4th Street, Suite 1600
Louisville, KY 40202